{"analyses":[{"ciLowerLimit":"0.595","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.636","estimateComment":"HR is from the Cox proportional hazards model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9580","paramType":"Hazard Ratio (HR)","paramValue":"0.986","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit could not be estimated because of the insufficient number of events","groupId":"OG000","lowerLimit":"42.0","upperLimit":"NA","value":"46.0"},{"comment":"Median and Upper limit could not be estimated because of the insufficient number of events","groupId":"OG001","lowerLimit":"43.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from the date of study drug randomization to death due to any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for those who discontinued from the study or were lost to follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From randomization to study completion (up to approximately 57 months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}